Access cutting-edge essential thrombocythemia treatment through this clinical trial at a research site in Ann Arbor. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Ann Arbor location
Access essential thrombocythemia specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related essential thrombocythemia treatment provided free
Check if you qualify for this essential thrombocythemia clinical trial in Ann Arbor, MI
No-Cost Study Care
Local to Ann Arbor
Convenient for MI residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
The purpose of this study is to evaluate the efficacy and safety of bomedemstat compared with hydroxyurea in cytoreductive therapy naïve essential thrombocythemia (ET) participants for whom cytoreductive therapy is indicated. Its primary objective is to compare bomedemstat to hydroxyurea with respect to durable clinicohematologic response (DCHR). The primary hypothesis is that bomedemstat is superior to hydroxyurea with respect to DCHR.
Sponsor: Merck Sharp & Dohme LLC
Yes, this clinical trial (NCT06456346) has an active research site in Ann Arbor, MI that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for essential thrombocythemia treatment options in Ann Arbor, MI, this clinical trial (NCT06456346) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Ann Arbor research site is actively enrolling participants for this clinical trial. You'll receive care from experienced essential thrombocythemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all essential thrombocythemia clinical trials near you to find additional studies recruiting in your area.
See all myeloproliferative neoplasms clinical trials recruiting in Ann Arbor — not just this study.
Browse Myeloproliferative Neoplasms Trials in Ann Arbor →